Sanguine Strategic Advisors Celebrates 5 Years of Business

Sanguine credits its success to founder Keven Chern and its ability to foster strong, long-lasting relationships with its client network.

United States - October 31, 2024 —

Sanguine Strategic Advisors is pleased to announce its fourth anniversary in business giving entrepreneurs and business owners sound advice on refining and expanding their product and service offerings. The company has built its success on its ability to identify and implement optimal solutions for company operations, helping teams focus only on the highest-impact activities. 

Kevin Chern is the brains behind Sanguine Strategic Advisors. The multi-award-winning entrepreneur and legal expert founded the company in 2019 to teach other businesses about the operations they could outsource and provide solutions.

“I noticed that many firms were managing human resources, inventory, marketing, and finances in-house, dealing with all the complexities themselves,” Chern explains. “However, it was clear to me as someone with experience in the field that none of this was necessary for many brands. Most would be better off focusing on their core concepts and externalizing the rest.”

This insight allowed Sanguine to bring its extensive operational insight to the table. The company ensures its clients develop the best strategies and partners to flourish, helping them avoid bloat and burdensome administration. This unique approach led the firm to appear at number 94 on Inc. magazine’s prestigious Inc.5000 list of America’s highest-performing and most innovative companies. The publisher recognized Sanguine’s ability to leverage business development and operations expertise to enhance its clients’ operations. 

Sanguine Strategic Advisor’s success comes as little surprise to those who know the company. Chern has built multiple eight-figure businesses over his 30-year career, blending his business skills with his knowledge as an attorney. He has now brought together a talented team, embodying his optimism and insightful approach to business operations, building a strong reputation throughout the company’s extensive client base and beyond. 

“We believe that managing a business should feel rewarding, not overwhelming,” Chern explains. “That’s why we’re now enjoying our fifth year in business. We aim to simplify the learning process for operations and help companies find the right partners for their needs quickly. Quite frankly, it’s a thrill.”

Sanguine continues to cultivate relationships with its network of solutions providers to ensure client firms receive the highest-quality outsourcing. Customer service teams are always available to address client issues while outsourcing and put their operations on a sustainable path. 

For more information about Sanguine Strategic Advisors, use the following contact details: 

Website URL: sanguinesa.com

Contact Name: Kevin Chern

Contact Email: [email protected]

Contact Phone: 844-394-6946

Contact Info:
Name: Kevin Chern
Email: Send Email
Organization: Sanguine Strategic Advisors
Phone: 844-394-6946
Website: https://sanguinesa.com/about-sanguine-strategic-advisors/

Release ID: 89143687

In the event of detecting errors, concerns, or irregularities in the content shared in this press release that require attention or if there is a need for a press release takedown, we kindly request that you inform us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your feedback within 8 hours and take necessary actions to resolve any identified issues diligently or guide you through the removal process. Providing accurate and dependable information is our utmost priority.

You May Also Be Interested In

• LINK PBC EARNS B CORP(TM) CERTIFICATION AND TURNS “DESIGN FOR GOOD” INTO GROWING BUSINESS MODEL
• West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
• Capital One Announces Full Redemption of Its Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series M